The year 2025 has been a pivotal period for thoracic oncology, characterized by a series of landmark approvals from the FDA that further segment the treatment landscape of non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)….
2025 FDA Lung Cancer Approvals: Precision Medicine and Immunotherapy Advances | Targeted Oncology
